Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.48 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL835436 | 0.85 | MAPK1 (0.52) | SIRT2MAPTTSHRMAPK1TDP1 | |
| SCHEMBL6980080 | 0.84 | MAPT (0.57) | MAPTTSHRERCC1ERCC4MAPK1 | |
| SCHEMBL9670480 | 0.80 | MAPT (0.58) | MAPTTSHRERCC1ERCC4MAPK1 | |
| SCHEMBL3105661 | 0.79 | MAPK1 (0.50) | MAPTTSHRMAPK1TDP1NPC1 | |
| SCHEMBL18704028 | 0.77 | NOTUM (0.55) | SIRT2MAPTALDH1A1 | |
| SCHEMBL25801547 | 0.76 | NPC1 (0.56) | MAPTTSHRERCC1ERCC4MAPK1 | |
| SCHEMBL1335806 | 0.74 | MAPK1 (0.48) | MAPTTSHRMAPK1NPC1HTT | |
| Hydroxyamine SCHEMBL6570268 | 0.73 | CYP1A2 (0.44) | MAPTTSHRMAPK1NPC1HTT | |
| Gr-175737 SCHEMBL195040 | 0.73 | MAPT (0.49) | MAPTTSHRMAPK1TDP1 | |
| SCHEMBL4230085 | 0.73 | MAPT (0.46) | MAPTTSHRERCC1ERCC4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272848-B1 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| CN-101282977-B | Xanthine derivatives as selective hm74a agonists | SMITHKLINE BEECHAM CORP | 2011-07-27 | — | — | CN | disclosed |
| EP-2272848-A1 | Xanthine derivatives as selective HM74A agonists | Glaxosmithkline LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
| CN-101282976-A | Xanthine derivatives as selective HM74A agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| CN-101282977-A | Xanthine derivatives as selective hm74a agonists | SMITHKLINE BEECHAM CORP (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1912992-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1912991-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SmithKline Beecham Corporation (US) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007017261-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017262-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | SIRT2 2411/4885MAPT 3948/4885TSHR 443/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | SIRT2 2567/4885MAPT 4108/4885TSHR 525/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | SIRT2 2556/4885MAPT 4059/4885TSHR 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.